Media stories about Radius Health (NASDAQ:RDUS) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Radius Health earned a news impact score of 0.25 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.6754512122021 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several equities analysts recently issued reports on the stock. Maxim Group reissued a “positive” rating on shares of Radius Health in a report on Friday, September 29th. They noted that the move was a valuation call. Canaccord Genuity set a $85.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research report on Monday, July 17th. BidaskClub cut shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cantor Fitzgerald set a $65.00 price objective on shares of Radius Health and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $45.00 price objective on shares of Radius Health in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $52.17.
Shares of Radius Health (NASDAQ RDUS) traded down 5.48% on Thursday, reaching $31.05. 1,098,859 shares of the company were exchanged. Radius Health has a 12 month low of $31.01 and a 12 month high of $55.97. The company’s market cap is $1.35 billion. The company’s 50-day moving average price is $36.21 and its 200 day moving average price is $38.54.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.23). The firm had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same quarter in the previous year, the business earned ($1.01) earnings per share. On average, equities research analysts expect that Radius Health will post ($5.41) EPS for the current year.
In other news, major shareholder Growth N. V. Biotech purchased 50,000 shares of Radius Health stock in a transaction that occurred on Tuesday, September 5th. The shares were bought at an average cost of $36.75 per share, with a total value of $1,837,500.00. Following the completion of the purchase, the insider now directly owns 5,298,799 shares in the company, valued at $194,730,863.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Growth N. V. Biotech purchased 60,000 shares of Radius Health stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average cost of $35.98 per share, for a total transaction of $2,158,800.00. Following the completion of the purchase, the insider now owns 5,248,799 shares of the company’s stock, valued at $188,851,788.02. The disclosure for this purchase can be found here. Insiders have bought 469,100 shares of company stock worth $16,328,382 over the last three months. Insiders own 15.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Radius Health (RDUS) Getting Somewhat Positive Press Coverage, Report Shows” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/26/radius-health-rdus-earns-daily-media-impact-rating-of-0-25.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.